Checkpoint Inhibitors in Malignant Pleural Mesothelioma
0 Visualizações
• 07/02/23
0
0
Embutir
administrator
Assinantes
Mark Socinski, MD; Mary Jo Fidler, MD; Roy Herbst, MD, PhD; Geoffrey Oxnard, MD; and Naiyer Rizvi, MD discuss the potential for checkpoint inhibitors, such as pembrolizumab, for malignant mesothelioma. Also discussed is the importance of trials that can be done in the community setting.
Mostre mais
Comentários do Facebook
SORT BY-
Melhores Comentários
-
Últimos Comentários